Abstract
Toxoplasma gondii (T. gondii) is the most common cause of secondary central nervous system infection in immunocompromised persons such as AIDS patients. Dihydrofolate reductase and thymidylate synthase enzymes have been studied as attractive targets against parasitic diseases, since they are involved in cell proliferation and influence on DNA synthesis. In this paper, we propose three-dimensional structures of T. gondii dihydrofolate reductase and thymidylate synthase based on homology modeling. In addition, we assessed the interaction mode of pyrimidine analogs in the active site of T. gondii and human enzymes, in order to direct the planning of new compounds that can be used against toxoplasmosis. According to the docking studies, predicted pIC50 values for proposed compounds were higher than those of the experimentally most active compound.
Keywords: Molecular modeling, toxoplasmosis, dihydrofolate reductase and thymidylate synthase.
Current Bioactive Compounds
Title:Interactions of Pyrimidine Derivatives with Dihydrofolate Reductase and Thymidylate Synthase: Directions Toward Combating toxoplasmosis
Volume: 9 Issue: 2
Author(s): Letícia C. Assis, Letícia Santos-Garcia, Teodorico C. Ramalho and Elaine F. F. da Cunha
Affiliation:
Keywords: Molecular modeling, toxoplasmosis, dihydrofolate reductase and thymidylate synthase.
Abstract: Toxoplasma gondii (T. gondii) is the most common cause of secondary central nervous system infection in immunocompromised persons such as AIDS patients. Dihydrofolate reductase and thymidylate synthase enzymes have been studied as attractive targets against parasitic diseases, since they are involved in cell proliferation and influence on DNA synthesis. In this paper, we propose three-dimensional structures of T. gondii dihydrofolate reductase and thymidylate synthase based on homology modeling. In addition, we assessed the interaction mode of pyrimidine analogs in the active site of T. gondii and human enzymes, in order to direct the planning of new compounds that can be used against toxoplasmosis. According to the docking studies, predicted pIC50 values for proposed compounds were higher than those of the experimentally most active compound.
Export Options
About this article
Cite this article as:
Assis C. Letícia, Santos-Garcia Letícia, Ramalho C. Teodorico and Cunha F. F. da Elaine, Interactions of Pyrimidine Derivatives with Dihydrofolate Reductase and Thymidylate Synthase: Directions Toward Combating toxoplasmosis, Current Bioactive Compounds 2013; 9 (2) . https://dx.doi.org/10.2174/22115528112019990010
DOI https://dx.doi.org/10.2174/22115528112019990010 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders
Current Pharmaceutical Design Vpu: A Multifunctional Protein that Enhances the Pathogenesis of Human Immunodeficiency Virus Type 1
Current HIV Research The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Antimicrobial Stewardship in the Neonatal Intensive Care Unit: An Update
Current Pediatric Reviews Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Role of Interleukin-21 in Inflammation and Allergy
Inflammation & Allergy - Drug Targets (Discontinued) The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Gene therapy for Multiple Myeloma
Current Gene Therapy Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Delayed Treatment with Nicotinamide Inhibits Brain Energy Depletion,Improves Cerebral Microperfusion, Reduces Brain Infarct Volume, but does not Alter Neurobehavioral Outcome Following Permanent Focal Cerebral Ischemia in Sprague Dawley Rats
Current Neurovascular Research Macrophage Activation Syndrome in Childhood Rheumatic Diseases
Current Rheumatology Reviews Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Biomaterials and Mesenchymal Stem Cells for Regenerative Medicine
Recent Patents on Biotechnology Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Current Pharmaceutical Design Risks of Self-Medication Practices
Current Drug Safety Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology Evaluation of the Biological Fate and the Transport Through Biological Barriers of Nanosilver in Mice
Current Pharmaceutical Design Graphene-based Biosensors for Biomolecules Detection
Current Nanoscience